US 12,076,562 B2
Systems and methods for the treatment of pain through neural fiber stimulation
Maria E. Bennett, Beachwood, OH (US); Joseph W. Boggs, Chapel Hill, NC (US); Warren M. Grill, Chapel Hill, NC (US); and John Chae, Strongsville, OH (US)
Assigned to SPR Therapeutics, Inc., Cleveland, OH (US)
Filed by SPR Therapeutics, Inc., Cleveland, OH (US)
Filed on Mar. 24, 2023, as Appl. No. 18/125,898.
Application 18/125,898 is a continuation of application No. 16/937,680, filed on Jul. 24, 2020, granted, now 11,612,746.
Application 16/937,680 is a continuation of application No. 15/854,206, filed on Dec. 26, 2017, granted, now 10,722,715, issued on Jul. 28, 2020.
Application 15/854,206 is a continuation of application No. 15/453,978, filed on Mar. 9, 2017, granted, now 9,855,427, issued on Jan. 2, 2018.
Application 15/453,978 is a continuation of application No. 14/336,633, filed on Jul. 21, 2014, granted, now 9,616,229, issued on Nov. 6, 2017.
Application 14/336,633 is a continuation of application No. 13/309,024, filed on Dec. 1, 2011, granted, now 8,788,046, issued on Jul. 22, 2014.
Application 13/309,024 is a continuation in part of application No. 13/294,875, filed on Nov. 11, 2011, granted, now 10,668,285, issued on Jun. 2, 2020.
Claims priority of provisional application 61/418,801, filed on Dec. 1, 2010.
Claims priority of provisional application 61/418,768, filed on Dec. 1, 2010.
Claims priority of provisional application 61/412,685, filed on Nov. 11, 2010.
Prior Publication US 2023/0248975 A1, Aug. 10, 2023
Int. Cl. A61N 1/36 (2006.01)
CPC A61N 1/36071 (2013.01) [A61N 1/36003 (2013.01); A61N 1/36017 (2013.01); A61N 1/36021 (2013.01); A61N 1/36057 (2013.01)] 33 Claims
OG exemplary drawing
 
1. A method comprising:
positioning a lead comprising an electrode, wherein the electrode is at a therapeutically effective distance from a target efferent nerve fiber; and
electrically stimulating through the electrode the target efferent nerve fiber to induce an action potential in the target efferent nerve fiber while avoiding generation of action potentials in a non-target nerve fiber, wherein the target efferent nerve fiber is neurologically upstream from a perceived point of pain, wherein the therapeutically effective distance is greater than 1 mm from the target efferent nerve fiber.